健帆生物：主动下调KHA130产品价格，目前对整体毛利率影响较小

Core Viewpoint - The company is proactively reducing the price of its KHA130 blood perfusion device to 339 yuan starting from September 2025 to fulfill social responsibility and respond to market competition [1] Group 1: Pricing Strategy - The price reduction for the KHA130 blood perfusion device will be implemented across various provinces, with the specific timing dependent on local platforms [1] - The KHA130 accounted for 5.22% of the company's revenue in the first three quarters of 2025 [1] Group 2: Financial Impact - The price reduction initiative has not significantly affected the company's overall gross margin to date [1] - Future impacts on financial performance will depend on the effectiveness of market promotion efforts, with updates to be disclosed in regular reports [1]